Affle (India) Limited vs Dr. Reddy's Laboratories Limited
Put two companies head-to-head — source-verified financials and AI-analysed SWOT, together in one view.
Affle (India) Limited (Advertising technology) and Dr. Reddy's Laboratories Limited (Pharmaceuticals) go head-to-head here — with source-verified financials and a full SWOT breakdown side by side on Nexvora Intelligence. On the figures reported, Dr. Reddy's Laboratories Limited leads on Revenue (approx.).
Dr. Reddy's Laboratories Limited leads on Revenue (approx.).
Head-to-head highlights
| Metric | Affle (India) Limited | Dr. Reddy's Laboratories Limited | Basis |
|---|---|---|---|
| Revenue (approx.) | Approximately ₹1,800-1,900 crore | Approximately US$3.3 billion to US$3.5 billion, unverified and converted from reported Indian rupee revenue | AI estimate |
An arrow marks the larger reported figure — a factual comparison, not a quality judgement. Verified figures come from official filings; AI estimates are approximate and unverified.
Affle (India) Limited
Advertising technology · India
Affle (India) Limited is an Indian advertising technology company focused on mobile marketing, user acquisition, and consumer intelligence. Its platforms help advertisers acquire, engage, and monetize users across mobile apps and digital channels, with a strong focus on India and other emerging markets.
Verified financials
No source-verified financials available.
Strengths
- Strong mobile-first adtech specialization
- Performance-based advertising model aligned with advertiser ROI
- Presence across India, Southeast Asia, and other growth markets
- Portfolio expanded through acquisitions such as Jampp, mediasmart, and RevX
Weaknesses
- Smaller scale than global platform giants
- Dependence on mobile advertising budgets
- Business complexity from multiple acquired platforms
- Exposure to margin pressure in competitive performance marketing
Opportunities
- Growth in mobile app ecosystems across emerging markets
- Rising advertiser demand for measurable performance marketing
- Expansion of AI-driven campaign optimization and consumer intelligence
- Cross-selling across acquired adtech platforms
Threats
- Privacy regulation and mobile identifier restrictions
- Competition from large walled-garden platforms
- Ad fraud and brand-safety concerns in digital advertising
- Macroeconomic slowdowns affecting advertising spend
Dr. Reddy's Laboratories Limited
Pharmaceuticals · India
Dr. Reddy's Laboratories Limited is an Indian multinational pharmaceutical company focused on generic medicines, active pharmaceutical ingredients, biosimilars, and branded formulations. The company operates across regulated and emerging markets, with a significant presence in India, North America, Europe, and other international markets.
Verified financials
No source-verified financials available.
Strengths
- Established global generics and API manufacturing capabilities
- Strong presence in India and regulated international markets
- Growing biosimilars and complex generics pipeline
- Experience navigating pharmaceutical regulatory approvals
Weaknesses
- Exposure to pricing pressure in the U.S. generics market
- Dependence on regulatory compliance across multiple jurisdictions
- Product concentration risk in certain key markets
- High ongoing investment needs for R&D and quality systems
Opportunities
- Expansion in biosimilars and complex generics
- Growth in emerging markets and branded generics
- Portfolio expansion through acquisitions and licensing
- Increasing demand for affordable medicines globally
Threats
- Regulatory warnings or import restrictions from health authorities
- Intense generic drug price competition
- Patent litigation and delayed product approvals
- Currency volatility and supply chain disruptions
Frequently asked
Answered from source-verified figures on this page.
Affle (India) Limited vs Dr. Reddy's Laboratories Limited: which company leads overall?
Dr. Reddy's Laboratories Limited leads on Revenue (approx.).
AI Analyst
Insights and answers generated live from Affle (India) Limited vs Dr. Reddy's Laboratories Limited's verified data. Modeled estimates — not investment advice.